Our current study demonstrates that the suppression of G-CSFR signalling does not compromise host immunity to two major respiratory pathogens, in contrast to broader anti-inflammatory agents such as corticosteroids that are routinely used to treat patients with chronic inflammatory conditions such as asthma and arthritis. The gene discussed is CSF3R; the disease is asthma.